drugset / Trial / NCT01915849

Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus

NCT01915849

Phase 1/2 Completed 14 enrolled Novartis Pharmaceuticals
RandomizedCrossoverDouble-blind

Summary

The purpose of the study was to assess the effect of LIK066 on intestinal glucose absorption immediately after a single dose (immediate effect) and 6 hours following the dose (after multiple daily doses; sustained effect) in patients with type 2 diabetes mellitus (T2DM).

Timeline

Start
2013-07
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject licogliflozin Small molecule 15 mg Oral
Subject licogliflozin Small molecule 50 mg Oral
Subject licogliflozin Small molecule 150 mg Oral